Contract facts
FederalNo full NAICS 325413 intel page yet. Browse NAICS intelligence
WAIVED BLOOD TESTING PT-INR LEASE&REAGENTS is a federal award for 257-Network Contract Office 17 (36C257) held by Roche Diagnostics Corp. Estimated value $133K ($45K obligated). Current period of performance ends Jun 30, 2024. Last award drew 1 bidder. Place of performance: INDIANAPOLIS IN.
WAIVED BLOOD TESTING PT-INR LEASE&REAGENTS
Recompete timing
PublicCurrent PoP ended Jun 30, 2024 (823 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on 36C25719N0512? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordRoche Diagnostics Corp — $245.9M obligated across 1,391 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C25719N0512?
36C25719N0512 (WAIVED BLOOD testing pt-inr lease&reagents) is a 257-Network Contract Office 17 (36C257) award with a potential value of $133K, currently held by Roche Diagnostics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C257-19-N-0512?
36C257-19-N-0512 is the dashed form of PIID 36C25719N0512 (WAIVED BLOOD testing pt-inr lease&reagents), held by Roche Diagnostics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C25719N0512?
257-Network Contract Office 17 (36C257) awarded 36C25719N0512 to Roche Diagnostics Corp (potential $133K).
Who is the incumbent on 36C25719N0512?
Roche Diagnostics Corp is the incumbent with $245.9M across 1391 related awards in SCOUT’s public footprint. The current period of performance ends Jun 30, 2024.
When does Roche Diagnostics Corp’s 36C25719N0512 come up for recompete?
SCOUT tracks a period-of-performance end of Jun 30, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C25719N0512? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.